References
- Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi: 10.1093/infdis/jiu396.
- Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765. doi: 10.1172/JCI138745.
- Franchini M, Focosi D. Hyperimmune plasma and immunoglobulins against COVID-19: a narrative review. Life. 2024;14(2):214. doi: 10.3390/life14020214.
- Franchini M, Corsini F, Focosi D, et al. Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews. Diagnostics. 2021;11(9):1663. doi: 10.3390/diagnostics11091663.
- Khawaja T, Kajova M, Levonen I, et al. Double-blinded, randomized, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralizing antibodies homologous to donors’ variants. Infect Dis. 2024;56(6):423–433. doi: 10.1080/23744235.2024.2329957.
- Sullivan DJ, Focosi D, Hanley DF, et al. Outpatient randomized controlled trials to reduce COVID-19 hospitalization: systematic review and meta-analysis. J Med Virol. 2023;95(12):e29310. doi: 10.1002/jmv.29310.
- Franchini M, Focosi D, Percivalle E, et al. Variant of concern-matched COVID-19 convalescent plasma usage in seronegative hospitalized patients. Viruses. 2022;14(7):1443. doi: 10.3390/v14071443.
- Sullivan DJ, Franchini M, Senefeld JW, et al. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1. J Gen Virol. 2023;104(5):1854. doi: 10.1099/jgv.0.001854.
- Sullivan DJ, Franchini M, Joyner MJ, et al. Analysis of anti-SARS-CoV-2 omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat Commun. 2022;13(1):6478. doi: 10.1038/s41467-022-33864-y.
- Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 202;27(11):2012–2024. doi: 10.1038/s41591-021-01488-2.
- Thorlacius-Ussing L, Brooks PT, Nielsen H, et al. A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. Sci Rep. 2022;12(1):16385.
- Gharbharan A, Jordans CCE, GeurtsvanKessel C, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. 2021;12(1):3189. doi: 10.1038/s41467-021-23469-2.